Keywords
Cushing's disease
Depressive disorder
Guillain-Barré syndrome
Polyneuropathy
Psychiatric disorder
How to Cite
Abstract
Background: Guillain–Barré syndrome (GBS) is an inflammatory disease that affects the peripheral nervous system. Cushing’s disease (CD) is the most common type of endogenous Cushing syndrome (CS). Few literature reports are available on the coexistence between both diseases. We present a patient who developed Guillain–Barré syndrome-compatible polyneuropathy as a manifestation of Cushing's disease secondary to a Crooke cell tumor.
Objective: To recognize that most cases of hypercortisolism lack typical clinical features, healthcare personnel must maintain a high level of suspicion to ensure early diagnosis.
Case presentation: We present the case of a 64-year-old female patient with type 2 diabetes mellitus, hypertension, major depressive disorder, and a suicide attempt in the last year, who consulted the emergency department by exacerbation of her mood disorder after a fall with traumatic brain injury without loss of consciousness. She presented symmetrical, progressive, distal to proximal progressive weakness due to Guillain-Barré syndrome. However, hypokalemia secondary to Cushing’s disease caused by a pituitary adenoma was documented. Treatment with intravenous immunoglobulin and transsphenoidal surgery were carried out. Histopathological study confirmed ACTH-producing Crooke’s cell adenoma. Both mobility, electrolytes, and the mood disorder improved after treatment.
Discussion: This case highlights a patient with nonspecific symptoms, an unusual presentation of a known pathology, and a rare etiopathological origin, making it valuable to examine and discuss.
Conclusions: Guillain-Barré syndromes are usually sporadic. There are few cases documenting concomitance between Cushing’s and Guillain-Barré syndromes, this being the first case describing Crooke cell-type ACTH-producing pituitary tumor.
References
Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019 Nov 1;15(11):671–83. https://doi.org/10.1038/s41582-019-0250-9
Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. The Lancet. 2006:367(9522):1605-1617. https://doi.org/10.1016/s0140-6736(06)68699-6
Pivonello R, de Martino MC, de Leo M, Simeoli C, Colao A. Cushing’s disease: the burden of illness. Endocrine. 2017;56(1):10–8. https://doi.org/10.1007/s12020-016-0984-8
Cortez GM, Monteiro A, Agnoletto G, Bit-Ivan EN, Sauvageau E, Hanel RA. Aggressive Pituitary Tumor with Crooke’s Cells and Invasion of the Posterior Fossa. World Neurosurgery. 2020 Jun 1;138:138:530-534.e1. https://doi.org/10.1016/j.wneu.2020.02.137
Di Ieva A, Davidson JM, Syro LV, Rotondo F, Montoya JF, Horvath E, et al. Crooke’s Cell Tumors of the Pituitary. Neurosurgery. 2015 May 1;76(5):616–22. https://doi.org/10.1227/NEU.0000000000000657
Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Obesity research. 1994;2(5):486–508. https://doi.org/10.1002/j.1550-8528.1994.tb00097.x
Steffensen C, Bak AM, Zøylner Rubeck K, Jørgensen JOL. Epidemiology of Cushing’s syndrome. Neuroendocrinology. 201:92(Suppl. 1): 1–5. https://doi.org/10.1159/000314297
Nieman LK. Diagnosis of Cushing’s Syndrome in the Modern Era. Endocrinol Metab Clin NorthAm. 2018;47(2):259–73. https://doi.org/10.1016/j.ecl.2018.02.001
Penezi? Z, Zarkovi? M, Vujovi? S, Drezgi? M. Diagnosis and differential diagnosis of Cushing’s syndrome. Endo Rev. 2006;19(5):558–66. https://doi.org/10.1210/edrv.19.5.0346
Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJSA, Wassenaar MJE, Middelkoop HAM, et al. Subtle cognitive impairments in patients with long-term cure of Cushing’s disease. J Clin Endocrinol Metab. 2010;95(6):2699–714. https://doi.org/10.1007/s11102-013-0511-3
de Freitas MRG, Vidal CM, Orsini M. Guillain-barré syndrome: Celebrating a century. Arquivos de Neuro-Psiquiatria. 2017 Aug 1;75(8):600–3. https://doi.org/10.1590/0004-282X20170093
Yuki N, Hartung H-P. Guillain–Barré Syndrome. N Engl J Med. 2012 Jun 13;366(24):2294–304. https://doi.org/10.1056/NEJMra1114525
Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(1):33–43. https://doi.org/10.1093/brain/awt285
Bressler R, Johnson ST. Cushing’s syndrome and the Guillain-Barré syndrome. Annuals of Internal Medicine. 1959;50(6). https://doi.org/10.7326/0003-4819-50-6-ccli
Moeindarbary S, Abbasi Dalooei M, Ghahremani S, Tafrishi R, Ghazanfarpour M, Fazeli F, et al. Guillain-Barre Syndrome following Cushing’s Syndrome in a Pregnant Woman: A Case Report. Int J Pediatr 2019;7(72):12. https://doi.org/10.22038/IJP.2019.45349.3721
Newell-Price J, Trainer P, Besser M, Grossman A. The Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States. Endo Rev. 1998;19(5):647-672. https://doi.org/10.1210/edrv.19.5.0346
Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S, Saeger W. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007 Feb;156(2):203–16. https://doi.org/10.1530/eje.1.02326
Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017;28(3):228–43. https://doi.org/10.1007/s12022-017-9498-z
di Ieva A, Davidson JM, Syro L v, Rotondo F, Montoya JF, Horvath E, et al. Crooke’s Cell Tumors of the Pituitary. Neurosurgery. 2015 May 1;76(5):616–22. https://doi.org/10.1227/NEU.0000000000000657
Cohen IR, Stavy L, Feldman M. Glucocorticoids and cellular immunity in vitro. J Exp Med. 1970 Dec 1;132(6):1055–70. https://doi.org/10.1084/jem.132.6.1055
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Revista Colombiana de Endocrinología, Diabetes & Metabolismo